Home Newsfeeds Amazon Accused FTC of Harassing Executives Including Jeff Bezos and Andy Jassy

Amazon Accused FTC of Harassing Executives Including Jeff Bezos and Andy Jassy

-FT https://www.ft.com/content/c97e5a4d-8c90-4cdd-b1f2-7c23d4bef431

byCharles Gross

August 16, 2022

1 minute read

-FT

https://www.ft.com/content/c97e5a4d-8c90-4cdd-b1f2-7c23d4bef431

Broadwind Bags $11M In New Tower Orders

By Akanksha Bakshi

August 23, 9:40 AM

Broadwind Inc (NASDAQ:BWEN) has received $11 million in new tower orders from a global wind turbine manufacturer. The company expects to…

BWEN

M8 Pharmaceuticals Signs An Exclusive Licensing Agreement With Supernus Pharmaceuticals To Seek Regulatory Approval And Commercialize Qelbree Under M8’s Trademark In Latin America

By Benzinga Newsdesk

May 7, 10:03 AM

M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ('Supernus'), a biopharmaceutical company focused

SUPN

Teva’s Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit

By Vandana Singh

July 5, 3:38 PM

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.

GSK

Bank of America, Johnson & Johnson And 3 Stocks To Watch Heading Into Tuesday

By Lisa Levin

October 17, 3:45 AM

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

BAC

Amazon Accused FTC of Harassing Executives Including Jeff Bezos and Andy Jassy

Related Posts

Broadwind Bags $11M In New Tower Orders

M8 Pharmaceuticals Signs An Exclusive Licensing Agreement With Supernus Pharmaceuticals To Seek Regulatory Approval And Commercialize Qelbree Under M8’s Trademark In Latin America

Teva’s Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit

Bank of America, Johnson & Johnson And 3 Stocks To Watch Heading Into Tuesday